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Abstract : Varicella-zoster virus (VZV) gene 63 encodes a protein with a predicted molecular mass of
30.5 kDa which has amino acid similarities with the immediate-early (IE) protein 22 (ICP-22) of
herpes simplex virus type 1. In order to study the expression of this protein during lytic and latent
infection, gene 63 was cloned in frame and downstream from the glutathione-S-transferase gene,
expressed as a fusion protein, and purified. In VZV-infected Vero cells, antibodies directed against this
protein detect two polypeptides of 45 and 38 kDa which are localized both in the cytoplasm and in the
nucleus. Using a sequential combination of transcription and protein synthesis inhibitors (actinomycin
D and cycloheximide, respectively), we demonstrated the immediate-early nature of this protein, which
can thus be named IE63. Using a rat model of VZV latency, we showed that IE63 is heavily expressed,
essentially in neurons, during latency. IE63 can also be detected in the skin of patients showing early
herpes zoster symptoms.
Varicella-zoster virus (VZV) is an alphaherpesvirus and the causative agent of two human diseases:
chicken pox, upon primary infection, and shingles, after reactivation of the latent virus from the dorsal
root ganglia. The biology of VZV and the mechanisms involved in latency and reactivation are not well
documented, mainly because of the poor growth of the virus in vitro, where it remains highly cell
associated. Consequently, a part of our knowledge of VZV is derived from the determination of its
nucleotide sequence (6) and from structural and functional comparisons with herpes simplex virus type
1 (HSV-1), another intensively studied alphaherpesvirus (5, 7). Tran-sient-cell-transfection assays with
plasmids containing VZV open reading frames (ORFs) were particularly useful for the assignment of
potential functions to some of the VZV proteins (2, 8, 9, 17, 24, 28).
The genome of VZV is composed of 71 ORFs encoding 68 proteins that seem to be regulated in a
manner similar to those of proteins of other alphaherpesviruses (11, 12). Particularly, the HSV-1
infectious cycle, which is generally used as a reference, is characterized by regulation of gene
expression in a cascade fashion (15). The viral genes are subdivided into three classes on the basis of
their expression kinetics. Immediate-early (IE or α) genes are transcribed just after virus penetration in
the cell, without any de novo viral protein synthesis (1, 3), and encode proteins playing an important
role in viral gene regulation (8, 10, 28, 35). Early (E or β) genes encode proteins necessary for DNA
synthesis (31), whereas late (L or γ) genes are expressed at the end of the infectious cycle, after DNA
replication, and encode structural proteins.
On the basis of the DNA sequence, the ORF-4-, -61-, -62-, and -63-encoded proteins are considered
homologous to HSV-1 ICP-27, -0, -4, and -22, respectively (6, 23, 27). However, in spite of their
overall sequence homologies, functional similarities between VZV and HSV-1 proteins seem to be
limited (22), and until now, only ORF-62 has been shown to encode an immediate-early protein (13).
The protein encoded by ORF-63 has homology with ICP-22 of HSV-1, whose functions are not very
well characterized (29, 30, 34). The regulatory functions of the ORF-63 protein in VZV have begun to
be clarified, showing evidence for down regulative capacities of IE62 expression (14,18). Important are
the presence, during latency, of different transcripts, which could include ORF-63 transcripts in human
sensory ganglia (4, 16), and the detection of abundant ORF-63 transcripts in ex-planted and cultured
human ganglia (39) as well as adult rat dorsal root ganglia studied as a VZV latency model (21, 32).
These observations plead for an important role of this polypeptide, probably both in the control of the
infectious cycle and in the maintenance of latency. We have thus focused on this important protein
encoded by ORF-63 in order to determine its kinetic class and to visualize it in latently infected cells of
dorsal root ganglia. Moreover, this protein is shown to be expressed early in human tissue during VZV
reactivation.
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Construction of recombinant pGex3X-ORF-63, expression of a GST-ORF-63-encoded protein,
and preparation of a rabbit antiserum.
ORF-63 lies in the left repeat flanking the short unique segment of the VZV genome from nucleotide
110581 to 111415 (6); an identical copy (ORF-70) is in the opposite orientation in the terminal short
repeat. We have chosen to express the ORF-63-encoded protein as a fusion polypeptide with
glutathione-S-transferase (GST) in Escherichia coli (37). The coding sequence of VZV gene 63 was
obtained by cutting the VZV EcoRI A fragment (21) first with restriction enzymes SpeI and SspI to
obtain a 4,027-bp fragment and then with restriction enzyme StyI to generate an 834-bp fragment
containing the ATG codon, to which a partially double-stranded oligonucleotide was added by ligation
to restore the 3' end. This fragment was introduced into the HindII site of pUC19 to obtain plasmid
pUC19-IE63 (P. Jacobs, University of Brussels, Nivelles, Belgium). The coding sequence of gene 63
was then cut out by digesting plasmid pUC19-IE63 with PstI and HindIII, filling in the 3' and 5'
termini with bacteriophage T4 DNA polymerase, and introducing the gene 63 coding sequence into the
SmaI site of pGex-3X (Pharmacia-LKB, Uppsala, Sweden) to obtain plasmid pGex-3X/ORF-63. Both
the junction of the GST gene and ORF-63 and the beginning of ORF-63 were sequenced. Bacteria
transformed with plasmid pGex-3X/ ORF-63 were induced by 1 mM IPTG (isopropyl-β-D-thioga-
lactopyranoside) for 3 h at 37°C. The bacteria were then sonicated in phosphate-buffered saline (PBS)–
Triton X-100 (1%, wt/vol) after centrifugation at 15,000 X g (4°C), and the GST-63 fusion protein was
released at a high concentration into the supernatant. This fusion protein was clearly visible as a 66-
kDa band electrophoresed on sodium dodecyl sulfate– 10% (wt/vol) polyacrylamide gel (SDS-10%
PAGE) stained with Coomassie blue compared with the crude extract of cells expressing the 27-kDa
GST protein alone (Fig. 1A). This supernatant was used for affinity chromatography on glutathione-
Sepharose-4B (Pharmacia-LKB, Uppsala, Sweden). The fusion protein GST-ORF-63 was eluted with
reduced glutathione (10 mM) (38), and an aliquot was loaded onto SDS-10% PAGE gels to ensure the
purity of the fusion protein (Fig. 1B). The GST-63 polypeptide was used, without any further
purification, for subsequent antibody production.
Antiserum against the GST-63 fusion protein was prepared by immunizing two rabbits with the
purified fusion protein. The first immunization was done subcutaneously with 0.2 mg of fusion protein
in 0.5 ml that had been emulsified with an equal volume of Freund’s complete adjuvant. The rabbits
were given booster immunizations on days 15, 30, 45, 60, and 75 with 0.2 mg of fusion protein in
Freund’s incomplete adjuvant. The antiserum was tested by enzyme-linked immunosorbent assay
against GST-63 and GST alone (data not shown) before being collected on day 90.
The antiserum was tested first by Western blotting (immu-noblotting) of extracts of VZV-infected and
noninfected Vero cells. The antiserum was able to detect two polypeptides of 45 and 38 kDa in
infected-cell extracts. No protein was evidenced in the noninfected-cell extracts (Fig. 1C). These two
molecular masses are far above the 30.5 kDa predicted by DNA sequence determination (6) for the
ORF-63-encoded protein, but this as well as the detection of two different polypeptides could be
explained by the presence of numerous potential phosphorylation sites. No antigens were detected in
our extracts by the anti-GST antibodies.
The antiserum (anti-63) was then tested by immunostaining of infected and noninfected Vero cells
fixed for 10 min in acetone. After fixation, the nonspecific sites were saturated with PBS-milk (15
g/liter) before being treated with the anti-63 antibodies and revealed by fluorescein-isothiocyanate-
conju-gated swine immunoglobulins to rabbit immunoglobulins. The cells were then observed by
fluorescence microscopy. The antiserum was able to detect the ORF-63-encoded protein both in the
cytoplasms and in the nuclei of the VZV-infected cells (Fig. 2A, B, and D).
The ORF-63-encoded protein is expressed as an immediate-early protein during the VZV
infectious cycle.
To analyze the expression and localization of the ORF-63-encoded protein during the viral infectious
cycle, cell-free virus was produced by shaking infected cells with 0.5-mm-diameter glass beads.
Infected Vero cells (at 80% cytopathic effect) were scraped into SPGA medium (218 mM sucrose, 3.8
mM KH2PO4, 7.2 mM K2HPO4, 4.9 mM sodium glutamate, 1% bovine albumin, and 10% fetal calf
serum) (33). Infected cells and glass beads were shaken for 10 s in a Mini Bead-Beater (Biospec
Products, Bartlesville, Okla.) and then centrifuged twice at 3,000 rpm at 20°C in an Eppendorf 5415C
centrifuge (Hamburg, Germany). Supernatants were used to infect MRC5 cells at confluency with a
multiplicity of infection of 5 X 10-4. Unadsorbed viruses were washed after 1 h, and infected MRC5
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cells were fixed for 10 min in acetone at various times postinfection (p.i.) (3, 6, 9, 12, 16, 20, and 24 h).
FIG. 1. (A) SDS-PAGE separation of proteins of pGEX-3X-transformed bacteria and of pGEX-
3X/GST-63-transformed bacteria. Lanes a and c, pellet; lanes b and d, supernatant. Ten micrograms of
each sample was loaded in duplicate. Molecular mass markers are shown in the rightmost lane. (B)
SDS-PAGE of the affinity-purified GST-63 fusion protein. (C) Western blotting of extracts of infected
and noninfected Vero cells, revealed with the anti-63 serum (diluted 1/500).
The cells were studied by immunostaining both with the anti-63 serum and with a monoclonal antibody
developed in our laboratory (VL8) and directed against glycoprotein I (gE), a late VZV protein (25).
Uninfected cells were subjected to the same treatment and tested with the two antibodies as negative
controls.
Immunofluorescence visualization of the protein encoded by ORF-63 revealed staining in the
cytoplasms and nuclei of infected cells 6 h p.i. (Fig. 2A). This strong staining was also detected with a
major localization in the nuclei of the infected cells fixed from 9 h p.i. (Fig. 2B) to 24 h p.i. (data not
shown). gE was detected only in the perinuclear endoplasmic reticula of infected cells at 20 h p.i. (Fig.
2E) and was localized in the endoplasmic reticula, and with a punctated form in all the cytoplasms at
24 h p.i. (Fig. 2F).
Published in : Journal of virology (1995), vol. 69, iss. 5, pp. 3240-3245
Status : Postprint (Author’s version)
FIG. 2. Immunofluorescence of MRC5 cells infected with VZV and treated (C and D) or not treated (A,
B, E, and F) with the inhibitors (Fig. 3) and revealed with the anti-63 serum (A to D) and the VL8
monoclonal antibody (E and F). Cells were fixed at 6 h (A and C), 9 h (B and D), 20 h (E), and 24 h
p.i. (F).
Detection of the ORF-63-encoded protein as early as 6 h p.i. indicates its involvement at the very
beginning of the viral cycle and suggests the importance of its regulatory properties (14, 18). The
presence of abundant ORF-63-encoded protein at 6 h p.i., like that of IE62 (13), which is a well-
defined immediate-early protein, and the results of two earlier studies which identified an immediate-
early protein of 43 kDa (20, 36), which is consistent with the molecular mass of the ORF-63-encoded
protein, suggest strongly that this protein belongs to the immediate-early class.
To demonstrate the immediate-early nature of the ORF-63-encoded protein, a set of MRC5 cells
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infected with cell-free VZV was treated with metabolic inhibitors (13), first with cycloheximide
(CHX), which blocks protein synthesis, and second with actinomycin D (ActD), a transcription
inhibitor.
FIG. 3. (A and B) Immunohistochemical detection of IE63 in lumbar dorsal root ganglia (A) and root
(B) sections of a VZV-infected rat. (Inset) Five-hundred-fold magnification of lumbar dorsal root
ganglia IE63-positive neurons. Most of the neurons were labelled, and the protein was cytoplasmic,
nuclear, or both. Some axons were also positive. Magnifications, X250 (A) and X500 (B). (C)
Immunohistochemical detection of IE63 on a cutaneous biopsy of an erythematous lesion of a patient
showing early signs of herpes zoster. Nuclear, perinuclear, and cytoplasmic staining was detected in
isolated keratinocytes and in a small spongiotic area (magnification, X500).
After adsorption of the virus for 1 h in the presence of CHX (100 μg/ml), the cells were washed three
times and incubated with CHX (100 μg/ml) for 5 h. After three washes, ActD-containing medium (10
μg/ml) was added to the cells for 18 h to block transcription. From 3 to 24 h p.i., the cells were fixed
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for 10 min in acetone and studied by immunostaining with both the an-ti-63 serum and the anti-gE
monoclonal antibody. The infected cells treated with CHX and ActD did not present any staining at 6 h
p.i. (Fig. 2C); however, at 9 h p.i. (3 h after removal of CHX), intense staining appeared in the
cytoplasms and nuclei, similar to the staining detected in the untreated cells (Fig. 2D). This staining
remained constant in cells fixed at 12, 16, 20, and 24 h p.i. (data not shown). When the cells were
tested with anti-gE, no signal was detected in infected cells treated with the inhibitors (data not shown).
The use of a sequential combination of inhibitors allows the demonstration of the immediate-early
nature of a protein (transcription without de novo viral protein synthesis) (1, 3, 15). The first metabolic
inhibitor, CHX, blocked protein synthesis for a period of 6 h, and only the transcripts of the immediate-
early proteins could be synthesized without any viral translation. After removal of CHX, ActD was
added to block transcription, allowing the translation of preexisting transcripts. The lack of synthesis of
gE, which is considered a late protein, under these conditions demonstrated the efficiency of the
inhibitor procedure. In the infected cells treated with the inhibitors, the ORF-63-encoded protein
appeared 3 h after removal of CHX (9 h p.i.) and could still be detected at 24 h p.i. Since the synthesis
of the protein was not blocked by this combination of inhibitors, we can conclude that the ORF-63-
encoded protein is an immediate-early protein and can rightfully be named IE63.
After having characterized the expression of the IE63 protein and demonstrated its immediate-early
nature, we have attempted to study the cellular localization of the IE63 protein in dorsal root ganglia of
latently infected rats and during virus reactivation in humans during shingles episodes.
IE63 localization in latently infected rat ganglia.
Abundant transcripts corresponding to IE63 have been detected in dorsal root ganglia of latently
infected adult rats (21, 32). We have thus searched for the expression of the protein in sections of
latently infected adult rat dorsal root ganglia. Four million VZV-infected Vero cells (80% cytopathic
effect) were inoculated into each adult rat’s footpad. The lumbar ganglia (L4, L5, and L6)
corresponding to the inoculation area were dissected 1 month after inoculation and then fixed in
formalin and embedded in paraffin. Five-micrometer sections were deparaf-finized and treated for
immunohistochemical staining. The an-ti-63 (diluted 1/250) and anti-gE (diluted 1/20) antibodies were
incubated for 30 min at 20°C. Slides were washed and incubated, first with biotinylated antibodies and
finally with alkaline phosphatase-conjugated streptavidin (Dako, Glostrup, Denmark), according to the
manufacturer’s instructions. The revelation was performed in the presence of new fuchsin as the
chromogen, and the slides were counterstained with Mayer’s hemalun. The IE63 protein was detected
essentially in neurons, indicated by the red precipitate, and the staining was either cytoplasmic, nuclear,
or both (Fig. 3A). Fifty to 80% of the neurons, depending on the section, were positive. Importantly,
some nonneuronal cells and several axons located at the beginning of the sciatic nerve were also
labelled (Fig. 3B). It should be mentioned that gE was never detected in these sections; thoracic ganglia
of infected rats and ganglia from noninfected animals were negative for the two antibodies (data not
shown). IE63 is thus strongly expressed during the latent phase of the infection and probably plays an
important role in the establishment or maintenance of latency.
IE63 expression in human skin during VZV reactivation.
Because IE63 is detected during latency and at the very beginning of a productive viral cycle in vitro,
we have looked for its expression during reactivation in the skin of 49 patients suffering from herpes
zoster symptoms. Skin specimens were obtained from these patients after local anesthesia was
administered. To prove the presence of VZV in these lesions, in situ hybridization was performed,
allowing the detection of VZV nucleic acids (26). The samples were formalin fixed, paraffin
embedded, and treated as described for the dorsal root ganglia. Positive IE63 immunostaining occurred
in the nuclei and cytoplasms of epidermal and infundibular keratinocytes (Fig. 3C). In 13 early
nonvesicular VZV lesions, the IE63 protein was already expressed in keratinocytes, while gE was not
yet detectable. In later stages of cutaneous zoster, i.e., in vesicles, the anti-IE63 and anti-gE antibodies
yielded comparable results (data not shown). No staining was found in normal skin or herpes simplex
lesions (data not shown).
Our results show that the ORF-63-encoded protein is expressed at the onset of the viral cycle and can
thus be classified as an immediate-early protein. We have also demonstrated the presence of the IE63
protein in latently infected cells of rat dorsal root ganglia and the early expression of the IE63 protein
in human skin during reactivation. These results demonstrate the importance of the IE63 protein during
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the viral productive cycle as well as during latency.
On the basis of the promoter structure and function, it has been suggested that the IE62 protein is the
only immediate-early protein (14), with other genes like ORF-4, -29, and -63 being transcribed later
(8,18). However, just as α-TIF does for HSV-1, the VZV IE62 protein, brought into the cell in large
quantities by the virus (19), transactivates a group of genes, including ORF-63 and ORF-63 (9), both
expressed without viral de novo synthesis.
A study of the time-dependent expression of the IE63 protein in latently infected cells and its
regulatory effects on various VZV gene promoters would help to elucidate the role of this protein in the
viral latent and productive cycles.
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